Preclinical development of semisynthetic saponin immunological adjuvant Titerquil-1055 in the context of an influenza vaccine

流感疫苗中半合成皂苷免疫佐剂 Titerquil-1055 的临床前开发

• 批准号: 10164671
• 负责人: TYLER MARTIN
• 金额: $ 4.43万
• 依托单位: ADJUVANCE TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-06-16 至 2020-12-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10164671
• 关键词: Adjuvant; Antibody Response; Antigens; Communicable Diseases; Dose; Fluzone; Hemagglutinin; Immunologic Adjuvants; Influenza A Virus, H1N1 Subtype; Phase; Saponins; Savings; Serological; T cell response; Testing; Vaccines; immunogenic; immunogenicity; influenza virus vaccine; preclinical development

Increasingly defined vaccines against infectious diseases are better tolerated but less immunogenic, requiring use of an immunological adjuvant for best effect. Adjuvance's semi-synthetic saponin adjuvant TiterQuil-1055 (TQL1055) has demonstrated efficacy with a variety of antigens with no detectable reactogenicity. The objectives of the Phase I project are to test whether TQL1055 can enhance the immunogenicity and efficacy of influenza vaccines, and to conduct IND enabling stability studies.

越来越明确的针对传染病的疫苗耐受性更好，但免疫原性更低，需要使用免疫佐剂才能达到最佳效果。佐剂公司的半合成皂素佐剂TiterQuil-1055 （TQL1055）已被证明对多种抗原有效，且无检测到的反应性。I期项目的目标是测试TQL1055是否可以增强流感疫苗的免疫原性和效力，并进行IND的稳定性研究。